Global PD-1 and PD-L1 Inhibitors Market Based on Drug type
Global PD-1 and PD-L1 Inhibitors Market Based on Disease Type
Global PD-1 and PD-L1 Inhibitors Market Based on Region
Europe PD-1 and PD-L1 Inhibitors Market by Country
North America PD-1 and PD-L1 Inhibitors Market by Country
Asia Pacific PD-1 and PD-L1 Inhibitors Market by Country
Latin America PD-1 and PD-L1 Inhibitors Market by Country
Middle East & Africa PD-1 and PD-L1 Inhibitors Market by Country
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global PD-1 and PD-L1 Inhibitors Market Snapshot
Chapter 4. Global PD-1 and PD-L1 Inhibitors Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Penetration & Growth Prospect Mapping
4.6. Clinical Trial/Pipeline Analysis
4.7. Industry Analysis – Porter’s Five Forces Analysis
4.8. Competitive Landscape & Market Share Analysis
4.9. Key Trends in the Market
Chapter 5. Market Segmentation 1: Drugs Estimates & Trend Analysis
5.1. Drugs Type & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Drugs:
5.2.1. Pembrolizumab
5.2.2. Nivolumab
5.2.3. Atezolizumab
5.2.4. Durvalumab
5.2.5. Avelumab
5.2.6. Cemiplimab
5.2.7. Sintilimab
5.2.8. Others
Chapter 6. PD-1 and PD-L1 Inhibitors Market Segmentation 2: Indication Estimates & Trend Analysis
6.1. Indication Analysis & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Indication:
6.2.1. Melanoma
6.2.2. NSCLC
6.2.3. Renal cell carcinoma
6.2.4. Urothelial bladder cancer
6.2.5. Hodgkins Lymphoma
6.2.6. Merkel cell carcinoma
6.2.7. Colorectal cancer
6.2.8. Others
Chapter 7. PD-1 and PD-L1 Inhibitors Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) estimates and forecasts by Drugs, 2021-2034
7.1.2. North America PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) estimates and forecasts by Indication, 2021-2034
7.1.3. North America PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) estimates and forecasts by Country, 2021-2034
7.1.3.1. U.S.
7.1.3.2. Canada
7.2. Europe
7.2.1. Europe PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Drugs, 2021-2034
7.2.2. Europe PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Indication, 2021-2034
7.2.3. Europe PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Country, 2021-2034
7.2.3.1. Germany
7.2.3.2. Poland
7.2.3.3. France
7.2.3.4. Italy
7.2.3.5. Spain
7.2.3.6. UK
7.2.3.7. Rest of Europe
7.3. Asia Pacific
7.3.1. Asia Pacific PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Drugs, 2021-2034
7.3.2. Asia Pacific PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Indication, 2021-2034
7.3.3. Asia Pacific PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Country, 2021-2034
7.3.3.1. China
7.3.3.2. India
7.3.3.3. Japan
7.3.3.4. Australia
7.3.3.5. Rest of Asia Pacific
7.4. Latin America
7.4.1. Latin America PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Drugs, 2021-2034
7.4.2. Latin America PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Indication, 2021-2034
7.4.3. Latin America PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Country, 2021-2034
7.4.3.1. Brazil
7.4.3.2. Rest of Latin America
7.5. MEA
7.5.1. MEA revenue PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Drug, 2021-2034
7.5.2. MEA revenue PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by country, 2021-2034
7.5.2.1. South Africa
7.5.2.2. Rest of MEA
Chapter 8. Competitive Landscape
8.1. Major M &A /Research Institutes Partnerships, Alliances, and Agreements
8.2. Funding Activities
8.3. Company Profiles
8.3.1. Merck Co.
8.3.2. Bristol-Myers Squibb
8.3.3. Roche
8.3.4. AstraZeneca
8.3.5. Pfizer
8.3.6. Jiangsu HengRui Medicine
8.3.7. Regeneron Pharmaceuticals
8.3.8. ONO PHARMACEUTICAL CO., LTD.
8.3.9. Eli Lilly and Company
8.3.10. Innovent Biologics, Inc.
8.3.11. BeiGene
8.3.12. Junshi Biosciences Co.
8.3.13. Biocad
8.3.14. 4D pharma plc.
8.3.15. Agenus Inc.
8.3.16. Calithera.
8.3.17. Curis, Inc.
8.3.18. Constellation Pharmaceuticals, Inc.
8.3.19. Compass Therapeutics
8.3.20. Corvus Pharmaceuticals
8.3.21. CytomX Therapeutics, Inc.
8.3.22. eFFECTOR Therapeutics, Inc.
8.3.23. Jounce Therapeutics, Inc.
8.3.24. MacroGenics, Inc.
8.3.25. Mirati Therapeutics, Inc.
8.3.26. Moderna, Inc.
8.3.27. MultiVir, Inc.
8.3.28. NovoCure Ltd.
8.3.29. NeoImmuneTech, Inc.
8.3.30. Syndax Pharmaceuticals
8.3.31. PrimeVax Immuno-Oncology Inc.
8.3.32. Incyte Corporation
8.3.33. Trillium Therapeutics Inc.
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.